KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Net Cash Flow (2016 - 2026)

Pacira BioSciences has reported Net Cash Flow over the past 17 years, most recently at -$14.3 million for Q1 2026.

  • For Q1 2026, Net Cash Flow fell 308.85% year-over-year to -$14.3 million; the TTM value through Mar 2026 reached -$139.3 million, down 239.88%, while the annual FY2025 figure was -$118.2 million, 195.69% down from the prior year.
  • Net Cash Flow for Q1 2026 was -$14.3 million at Pacira BioSciences, down from $11.4 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $63.0 million in Q2 2024 and troughed at -$358.8 million in Q1 2022.
  • A 5-year average of -$26.0 million and a median of $6.8 million in 2025 define the central range for Net Cash Flow.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 1125.15% in 2023 and later plummeted 13965.07% in 2025.
  • Year by year, Net Cash Flow stood at -$5.3 million in 2022, then skyrocketed by 1125.15% to $54.2 million in 2023, then tumbled by 43.13% to $30.8 million in 2024, then tumbled by 63.1% to $11.4 million in 2025, then plummeted by 225.57% to -$14.3 million in 2026.
  • Business Quant data shows Net Cash Flow for PCRX at -$14.3 million in Q1 2026, $11.4 million in Q4 2025, and -$153.0 million in Q3 2025.